Breast cancer research and treatmentHumansFemaleBreast NeoplasmsCyclin-Dependent Kinase 4Middle Aged
Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study.
Olivia Lavigne, François Poumeaud, Thibaut Reverdy, Van Tuat Huynh, Guillaume Roces, Gaulthier Poupin, Maureen Gouillou, Angélique Bobrie, Emma Donadille, Florence Dalenc, William Jacot, Julien Robert, Frédéric Fiteni
Published: 202610.1007/s10549-025-07893-2
Abstract
PURPOSE: The standard first-line treatment for patients with hormone receptor-positive (HR +) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer is cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrin…
Preview only. Read the full abstract at the source